Cantharidin
Ycanth (cantharidin) is a small molecule pharmaceutical. Cantharidin was first approved as Ycanth on 2023-07-21. It is used to treat molluscum contagiosum and warts in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Ycanth
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cantharidin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| YCANTH | Verrica Pharmaceuticals | N-212905 RX | 2023-07-21 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cantharidin 0.7% | unapproved drug other | 2019-05-17 |
| cantharidin 1% / podophyllum resin 5% / salicylic acid 30% | unapproved drug other | 2019-05-17 |
| ycanth | New Drug Application | 2024-11-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| warts | — | D014860 | B07 |
| molluscum contagiosum | EFO_0007375 | D008976 | B08.1 |
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Molluscum contagiosum | D008976 | EFO_0007375 | B08.1 | — | 3 | 2 | 1 | 1 | 7 |
| Warts | D014860 | — | B07 | — | 2 | — | 2 | 1 | 5 |
| Infectious skin diseases | D012874 | — | — | — | 2 | — | 1 | — | 3 |
| Condylomata acuminata | D003218 | EFO_0007147 | A63.0 | — | 1 | — | 1 | — | 2 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | — | 1 | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | 1 | — | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin diseases | D012871 | — | L00-L99 | — | 2 | — | — | 1 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | — | — | — | 2 |
| Papillomavirus infections | D030361 | — | — | — | 2 | — | — | — | 2 |
| Communicable diseases | D003141 | — | — | — | 2 | — | — | — | 2 |
| Virus diseases | D014777 | — | B34 | — | 2 | — | — | — | 2 |
| Viral skin diseases | D017193 | — | — | — | 2 | — | — | — | 2 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | 1 | — | — | — | 1 |
| Viral sexually transmitted diseases | D015229 | — | — | — | 1 | — | — | — | 1 |
| Tumor virus infections | D014412 | — | — | — | 1 | — | — | — | 1 |
| Dna virus infections | D004266 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 4 | — | — | — | — | 4 |
| Blister | D001768 | — | — | 4 | — | — | — | — | 4 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | — | — | — | — | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cantharidin |
| INN | cantharidin |
| Description | Cantharidin is a monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A. It has a role as an EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor and a herbicide. It is a monoterpenoid and a cyclic dicarboxylic anhydride. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1 |
Identifiers
| PDB | — |
| CAS-ID | 56-25-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL48449 |
| ChEBI ID | 64213 |
| PubChem CID | 5944 |
| DrugBank | DB12328 |
| UNII ID | IGL471WQ8P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,791 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
107 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use